Bayer's $7.25 Billion Roundup Settlement Gets Preliminary Approval — What Law Firms Need to Know

A Missouri state court judge granted preliminary approval on March 4, 2026, for Bayer's $7.25 billion class settlement to resolve approximately 65,000 active Roundup cancer claims — making it one of the largest mass tort settlements in U.S. history. The deal, filed in the 22nd Judicial Circuit Court in St. Louis, requires Bayer to deposit $500 million within 10 days for notification and administration, with declining capped annual payments stretching over 21 years.

The settlement arrives as Bayer's total Roundup litigation costs have exceeded $16 billion since acquiring Monsanto in 2018 — and as the U.S. Supreme Court prepares to hear oral arguments in Monsanto v. Durnell on April 27, a preemption case that could reshape failure-to-warn claims nationwide.

What the Settlement Covers

The class settlement, announced February 17, 2026, covers two groups: current plaintiffs with active non-Hodgkin lymphoma (NHL) claims filed before the preliminary approval date, and future claimants — individuals exposed to Roundup before February 17, 2026, who develop NHL within 16 years of final approval.

Individual compensation ranges from $5,000 to $250,000 based on three factors: cancer severity and NHL subtype, age at diagnosis, and exposure type. Occupational users — those with 80 or more hours of agricultural, industrial, or turf application work — qualify for higher tiers than residential users.

The structure differs significantly from Bayer's failed 2021 attempt at a $2 billion future claims settlement, which federal Judge Vince Chhabria rejected as "clearly unreasonable." This time, the deal was negotiated with six leading plaintiffs' firms — including Motley Rice, Seeger Weiss, and Holland Law Firm — and provides full compensation rather than a capped fund with a science panel.

The Opposition: 20,000 Plaintiffs Push Back

Not everyone is on board. Fourteen law firms representing nearly 20,000 plaintiffs filed motions to intervene, arguing the settlement was rushed — just 15 days between announcement and the preliminary approval hearing for a 600-page agreement. The opposing firms raised concerns about inadequate representation, an unfair tier structure favoring occupational users, and overly broad release provisions.

Class counsel called the intervention motion "rife with inaccuracies." Judge Boyer granted preliminary approval despite the objections, but the opt-out period running through June 4 gives dissenting plaintiffs a formal exit.

The SCOTUS Variable

The settlement's timing is inseparable from the Supreme Court. SCOTUS granted certiorari in Monsanto v. Durnell in January 2026, agreeing to decide whether federal pesticide labeling law preempts state failure-to-warn claims — the primary legal theory underlying Roundup litigation.

Oral arguments are scheduled for April 27, 2026 — before the June 4 opt-out deadline but likely before a decision is issued. The U.S. Solicitor General filed a brief in December 2025 supporting Bayer's petition, which plaintiffs' attorneys view as a signal that the government may side with preemption.

Bayer CEO Bill Anderson framed the dual strategy explicitly: "The proposed class settlement agreement, together with the Supreme Court case, provides an essential path out of the litigation uncertainty."

If SCOTUS rules in Bayer's favor, failure-to-warn claims — including those from plaintiffs who opt out — could be substantially foreclosed. That makes the opt-out calculus particularly high-stakes for firms advising Roundup clients.

What This Means for Law Firms

The Opt-Out Decision

Firms with Roundup inventory face a strategic decision before June 4. The settlement guarantees compensation in the $5,000–$250,000 range, but individual litigation has produced verdicts orders of magnitude higher — the $2.25 billion McKivison verdict in Pennsylvania (later reduced to $400 million) and the $2.1 billion Barnes verdict in Georgia in March 2025.

However, Bayer has won 14 of its last 20 trials, and a favorable SCOTUS ruling on preemption would undercut the strongest legal theory available. Firms must weigh guaranteed settlement payouts against the risk that individual cases become significantly harder to win.

Medical Records Are the Qualifying Evidence

Every claim under the settlement requires documented proof of two things: NHL diagnosis and Roundup exposure. Specifically, claimants need pathology reports confirming NHL subtype, oncology treatment records establishing diagnosis date and severity, and evidence of exposure type (occupational vs. residential) — which determines the compensation tier.

For occupational users seeking higher-tier payouts, employment records, agricultural application logs, and occupational health records become critical supporting documentation alongside the medical evidence.

The Bottom Line

Bayer's $7.25 billion Roundup settlement represents the largest single resolution attempt in a litigation saga that has cost the company over $16 billion. For the 65,000 claimants covered, it offers guaranteed compensation on a structured timeline. For the 20,000 plaintiffs whose attorneys oppose the deal, the opt-out period through June 4 is the window to preserve individual claims — with the understanding that SCOTUS could reshape the legal landscape before those cases reach trial.

For firms on either side of the opt-out decision, the immediate priority is the same: complete medical records documenting NHL diagnosis, treatment severity, and exposure history. Whether a case resolves through the settlement's tier system or through individual litigation, the medical evidence is the foundation.

Sources: Reuters, Bayer Press Release, Drugwatch, Law.com/National Law Journal, The New Lede, BusinessWire/Solicitor General Brief. Settlement terms per Bayer's February 17, 2026 filing.